Compass Therapeutics (CMPX) Accumulated Depreciation & Amortization (2019 - 2026)

Compass Therapeutics' Accumulated Depreciation & Amortization history runs 8 years deep, the most recent figure standing at $6.7 million for Q1 2026.

• In Q1 2026, Accumulated Depreciation & Amortization changed 0.23% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $6.7 million (changed 0.23% YoY), while the FY2025 annual figure was $6.6 million, up 4.34% from the prior year.
• Accumulated Depreciation & Amortization came in at $6.7 million for Q1 2026 at Compass Therapeutics, roughly flat from $6.6 million in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $6.7 million in Q3 2024 to a low of $5.2 million in Q2 2022.
• A 5-year average of $6.2 million and a median of $6.4 million in 2024 frame the typical range for Accumulated Depreciation & Amortization.
• Across the five-year window, Accumulated Depreciation & Amortization surged 2488.0% in 2022 and declined 1.43% in 2025, its largest moves.
• Compass Therapeutics' Accumulated Depreciation & Amortization stood at $5.6 million in 2022, then climbed by 12.55% to $6.3 million in 2023, then increased by 1.5% to $6.4 million in 2024, then rose by 4.34% to $6.6 million in 2025, then rose by 0.23% to $6.7 million in 2026.
• According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered $6.7 million, $6.6 million, and $6.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison